Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with


Aug 24, 2009 - Claudio Mapelli,† Sesha I. Natarajan,† Jean-Philippe Meyer,† Margarita M. Bastos,† Michael S. Bernatowicz,† Ving G. Lee,†. ...
0 downloads 0 Views 2MB Size

Recommend Documents


Aug 24, 2009 - Preclinical Candidate Optimization. # Diabetes Drug Discovery. Bristol-Myers Squibb Company Research & Development, Pennington, New Jersey 08534. † Department of Applied Biotechnologies, Bristol-Myers Squibb Company Research & Develo

Aug 29, 2016 - The free fatty acid receptor 4 (FFA4 or GPR120) has appeared as an interesting potential target for the treatment of metabolic disorders. At present, most FFA4 ligands are carboxylic acids that are assumed to mimic the endogenous long-

Aug 29, 2016 - ... cruzi, Leishmania amazonensis and Herpes Simplex Virus .... Nystrom , Vincent Rash , Thomas Rimele , Shane Roller , Sean Ross.

Chem. Lett. , 2014, 5 (4), pp 368–372. DOI: 10.1021/ml400491k. Publication Date (Web): January 27, 2014 ... Design and synthesis of novel δ opioid receptor agonists with an azatricyclodecane skeleton for improving blood-brain barrier penetration.

The results showed that the TPA molecule and the teleocidin sofa form could interact with the com- mon receptor through three hydrogen bonds, and the sofa.

Sep 19, 2013 - physiological effects through at least 14 receptor subtypes, all but one belonging ...... disease: On movement, mood, and madness. Mov. Disord.

Jan 27, 2014 - effects mediated by the KOR,4,5 the DOR is a promising medical target because it seems to induce neither addictive nor aversive effects.

Michel WeïwerQihong XuJennifer P. GaleMichael LewisArthur J. CampbellFrederick A. SchroederGenevieve C. Van de BittnerMichelle WalkAldo AmayaPing ...

Jun 1, 2011 - Dilip K. Tosh, Khai Phan, Francesca Deflorian, Qiang Wei, Zhan-Guo Gao, and Kenneth A. Jacobson*. Molecular Recognition Section ...

Jun 7, 2018 - Novel peptidic dual agonists of the glucagon-like peptide 1 (GLP-1) and glucagon receptor are reported to have enhanced efficacy over pure ...